Could a Pre-Surgery drug improve thyroid cancer outcomes?
NCT ID NCT04321954
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving the drug lenvatinib before surgery helps remove advanced thyroid cancer more completely. 29 adults with invasive thyroid cancer took lenvatinib for a short time before their operation. The goal was to see if more patients could have clear or nearly clear surgical margins, which may improve long-term control of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib (Lenvima), a drug taken orally
What this could lead to
If successful, this could make surgery for advanced thyroid cancer more effective by shrinking tumors beforehand, potentially leading to better outcomes.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. Lenvatinib can cause side effects like high blood pressure and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States